

Glanbia plc

Statement on Equity Placement

Glanbia plc, the Better Nutrition company ("**Glanbia**" or "the **Company**"), has been informed by Tirlán Co-operative Society Limited ("**Tirlán**") that it intends to sell up to 17,000,000 ordinary shares (the "**Equity Placement Shares**") in Glanbia in order to finance the concurrent repurchase of Tirlán's outstanding €250 million 1.875 per cent Secured Exchangeable Bonds, due 27 January 2027 (ISIN: XS2436579978). The Equity Placement Shares represent approximately 7% of Glanbia's share capital.

The Equity Placement Shares are being offered to institutional investors by way of an accelerated bookbuild offering (the "**Equity Placement**"). Goodbody Stockbrokers UC ("**Goodbody**") and J&E Davy ("**Davy**") are acting as joint global coordinators and joint bookrunners in connection with the Equity Placement (Goodbody and Davy together the "**Joint Global Coordinators**"). Coöperatieve Rabobank U.A. in cooperation with Kepler Cheuvreux S.A. ("**Rabobank-Kepler Cheuvreux**") will act as joint bookrunner in connection with the Equity Placement (together with Goodbody and Davy, the "**Joint Bookrunners**").

Glanbia plc confirms it intends to participate in the Equity Placement by purchasing up to 45% of the Equity Placement Shares, subject to a maximum value of €100 million (the "**plc Participation Amount**"). Any shares purchased by the Company through this placement will be cancelled. The Board has approved a €50 million share buyback, additional to the €100 million authorised in February this year, to cover the plc Participation Amount.^[1]

Glanbia has entered into an agreement with Davy to act as principal in relation to the purchase of the Company's Shares from the Equity Placement, within certain pre-set parameters. This share buyback programme may be conducted by way of block trades in accordance with the Company's general authority to repurchase shares. The Company confirms that it currently has no unpublished inside information.

Glanbia's participation in the Equity Placement will be conducted within the limitations of the Company's general authority to repurchase shares as set out in Resolution 10 approved by the Company's shareholders at the 2025 Annual General Meeting on 30 April 2025 and up to a maximum of 10% of the issued share capital of the Company (being 25,634,283 ordinary shares which has been reduced to 21,245,761 ordinary shares following the completion of the latest buyback programme). Unless renewed, this authority will expire on the earlier of the close of business on the date on which the next Annual General Meeting of the Company is held in 2026 (expected to be in April 2026) or 31 July 2026.

Further details Glanbia's participation in the Equity Placement, including the value of the plc Participation Amount, will be published once the transaction has completed.

ENDS

For further information contact:

Glanbia plc

+353 56 777 2200

Mark Garvey, Chief Financial Officer

Liam Hennigan, Group Secretary & Head of Investor Relations:

+353 86 046 8375

Martha Kavanagh, Director of Corporate Affairs:

+353 87 646 2006

Davy

Ivan Murphy

+353 1 679 7788

^[1] In February 2025, Glanbia announced that its Board had approved a €100 million buyback authorisation. On 22 September Glanbia completed a €50 million share buyback programme under this authority. On 30 September 2025 the Board approved increasing this buyback authorisation by €50 million to fulfil Glanbia's participation in the Equity Placement.

END

MSCLMMATMTJUBIA